Table 5 Univariate analysis for estimating factors associated with a 3-month response after intravitreal injection of ranibizumab
Variables | P value* | OR (95Â % CI) |
|---|---|---|
Sex (male) | 0.521 | 1.635 (0.365–7.326) |
Age (years) | 0.945 | 1.004 (0.894–1.128) |
Eye (OD) | 0.237 | 0.400 (0.088–1.826) |
Lens status (phakic eye) | 1.000 | N/A |
Baseline subfoveal CT (μm) | 0.296 | 0.994 (0.984–1.005) |
Baseline mean peripapillary CT (μm) | 0.789 | 0.998 (0.981–1.015) |
Decreased amount of subfoveal CT (μm) | 0.097 | 1.030 (0.995–1.066) |
Decreased proportion of subfoveal CT (%) | 0.007 | 1.124 (1.033–1.223) |
Decreased amount of mean peripapillary CT (μm) | 0.094 | 1.041 (0.993–1.092) |
Decreased proportion of mean peripapillary CT (%) | 0.077 | 1.055 (0.994–1.120) |
Decreased amount of mean temporal peripapillary CT (μm) | 0.061 | 1.043 (0.998–1.090) |
Decreased proportion of mean temporal peripapillary CT (%) | 0.029 | 1.070 (1.007–1.137) |